Fundamental Analysis of Abcellera Biologics Inc - Growth / Value Index
ABCL - Valuation Highlights
Valuation Analysis
Undervalued - Price to Intrinsic Value of 0.0054
Book Value in last 3 years is trending up
Valuation Key Ratios
| Ratio | TTM | Latest FY | Yoy Change | MRQ |
|---|---|---|---|---|
| Price to Earning | -10.93 | 9.49 | 102.90 % | |
| Price to Book | 1.67 | 1.22 | -98.27 % | 5.26 |
| Price to Sales | 28.01 | 3.10 | -95.02 % | |
| Enterprise Value to EBITDA Multiple | -7.73 | 4.07 | 100.09 % |
ABCL - Profitability Highlights
Profitability Analysis
Piotroski F Score - Good Value of 7.0
Net profit has jumped from negative to positive
Company Earning excess return
Annual Net Profit in last 3 years is trending up
EBITDA is continuously increasing for last 3 Years
Good Return On Capital Employed of 12.85
Tsr Profitability Index - Poor Score of 20.62
Very Low Dividend Yield of 0 %
Negative Net Margin MRQ
Profitability Key Ratios
| Ratio | TTM | Latest FY | Yoy Change | MRQ |
|---|---|---|---|---|
| Return On Equity | -10.64 | 12.85 | 159.61 % | -2.42 |
| Return On Asset | -11.15 | 10.29 | 209.30 % | -4.83 |
| Net Profit Margin | -256.27 | 32.66 | 271.52 % | -433.55 |
| Operating Profit Margin | -411.29 | 46.78 | 231.93 % | -831.79 |
| EBITDA Margin | -258.25 | 56.91 | 4373.87 % | -508.27 |
Highlights
| Market Cap | 1387.01 M |
| Enterprise Value | 1006.06 M |
| Price/Book TTM | 1.67 |
| Outstanding Share | 290169 K |
| Float/ Outstanding Share | 65.89% |
| Dividend Yield | 0 % |
Share Holding
Guru Numbers
| Price/Graham No | 0 |
| Peter Lynch Ratio | 0 |
| Piotroski F Score | 7.0 |
| Altman Z Score | 4.63 |
| Sloan Ratio | 0.152 |
| Peter Lynch Fair Value | 0 |
ABCL - Growth Highlights
Growth Analysis
Tsr Growth Index - Excellent Score of 95.00
STRONG JUMP IN NET SALE : YoY growth
Annual sales of the company is increased for three years in a row
Steady increase in Total Assets for last 3 Years
Quarterly sales in last 5 Quarter is trending down
Growth Key Fields
| Field | TTM | YoY Growth | QoQ Growth |
|---|---|---|---|
| Revenue | 50392.00 K | 4080.53 % | 34.38 % |
| Gross Profit | 48838.00 K | 3508.37 % | 34.38 % |
| EBITDA | -130135.00 K | 178770 % | 3.54 % |
| Net Profit | -129141.00 K | 7270.55 % | 6.28 % |
| EPS | -0.437 | 3546.66 % | NA |
ABCL - Stability Highlights
Stability Analysis
Tsr Stability Index - Excellent Score of 95.00
Altman Z Score of 4.14 suggests good Stability
Cash ratio of 7.49
Company financial liquidity has improved
Stability Key Ratios
| Ratio | Latest FY | Yoy Change | MRQ |
|---|---|---|---|
| Debt to Equity Ratio | 0.0045 | -98.39 % | 0.0047 |
| Cash Ratio | 7.49 | -90.17 % | |
| Quick Ratio | 8.65 | 522.91 % | 8.33 |
| Shareholders Equity | 80.04 | 83.37 % | |
| Debt to EBITDA | 0.0202 | 100.11 % |
Historical Valuation Ratios of Abcellera Biologics Inc
Historical Valuation Ratios
Loading ...
Historical Profitability Ratios of Abcellera Biologics Inc
Historical Profitability Ratios
Loading ...
Historical Efficiency Ratios of Abcellera Biologics Inc
Historical Efficiency Ratios
Loading ...
Historical Solvency Ratios of Abcellera Biologics Inc
Historical Solvency Ratios
Loading ...
Note : All Data Generated at the End of Trading Hours (EOD Data)